"Mount Sinai’s Icahn School Launches $10M Investment Fund" - Jonathan LaMantia
The Icahn School of Medicine at Mount Sinai has created a $10 million accelerator fund to speed up the commercialization of research at the school. It's starting with two investments in drug-development ventures. The i3 Asset Accelerator will provide capital and business development support to its researchers. Icahn joins a growing group of local medical schools. "It was important for the institution to have a fund that could provide funding in a rapid format for a high-potential program," said Erik Lium, PhD, senior vice president of Mount Sinai Innovation Partners. "The kind of research we will be funding may not be the type of research that falls within the National Institutes of Health." Dr. Lium said he hopes to expand his team to ensure Mount Sinai can capitalize on opportunities that could ultimately translate into treatments.
- Erik Lium, PhD, Senior Vice President, Mount Sinai Innovation Partners, Icahn School of Medicine at Mount Sinai
- Ross L. Cagan, PhD, Senior Associate Dean, The Graduate School of Biomedical Sciences, Professor, Cell, Developmental and Regenerative Biology, Oncological Sciences, Ophthalmology, Icahn School of Medicine at Mount Sinai
- Arvin Dar, PhD, Assistant Professor, Oncological Sciences, Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
- Florian Krammer, PhD, Associate Professor, Microbiology, Icahn School of Medicine at Mount Sinai
Novel Drug Cocktails Strengthen Targeted Cancer Therapies While Lessening Side Effects
Aug 01, 2018 View All Press Releases